Blueprint RETreats As It Sells US Gavreto Rights To Rigel
Drug Will Be Pulled In Most Markets
After sales of the RET inhibitor have been commercially disappointing, Blueprint said it is selling US rights to the drug to Rigel for $15m up front and potentially more than $100m in milestones.
